Podcasts about wegovy

Popular GLP-1 medications like Ozempic, Wegovy, and Zepbound aren’t just transforming weight loss. They’re also changing our intimate lives in surprising ways. In today’s show, we’re diving into results from a new national study finding that a majority of people taking one of these medications reported a change in their sex and dating lives, for better or for worse. My guest is Dr. Amanda Gesselman a research scientist and head of the VIBES research team at the Kinsey Institute at Indiana University. Digital intimacy is a major focus of her research, including how people use tools like camsites, AI companions, dating apps, and social media to navigate connection and desire. Some of the specific topics we explore in this episode include: What specific changes are people noticing in their dating lives as a result of taking one of these drugs? Why does weight loss seem to be benefiting men more than women when it comes to dating? How do GLP-1 medications affect sexual health and function? And is it different for men and women? Are people taking GLP-1 medications worried about social judgement? To learn more, you can read a brief report about the study here. Got a sex question? Send me a podcast voicemail to have it answered on a future episode at speakpipe.com/sexandpsychology. *** Thank you to our sponsors!  Firmtech’s Tech Ring will help you to track your sexual health–and keep it up. Visit myfirmtech.com/justinlehmiller and use code JUSTIN15 for 15% off your purchase.  The Kinsey Institute is where the world turns to understand sex and relationships. You can help continue its expert-led research by donating to the Kinsey Institute Research Fund. Learn more and make a donation here: https://give.myiu.org/centers-institutes/I380010749.html  *** Want to learn more about Sex and Psychology? Click here for previous articles or follow the blog on Facebook, Twitter, or Bluesky to receive updates. You can also follow Dr. Lehmiller on YouTube and Instagram. Listen and stream all episodes on Apple, Spotify, or Amazon. Subscribe to automatically receive new episodes and please rate and review the podcast! Credits: Precision Podcasting (Podcast editing) and Shutterstock/Florian (Music). Image created with Canva; photos used with permission of guest.

Novo Nordisk, the pharmaceutical company behind popular GLP-1 medications like Wegovy and Ozempic, recently announced that its phase 3, two-year trial examining GLP-1 medications for Alzheimer's failed to produce a significant reduction in disease progression.While these results are discouraging, they may have revealed something vital about Alzheimer's treatment.In this video, Dr. Bret Scher breaks down the recent failure of Novo Nordisk's evoke and evoke+ trials and what it teaches us about the limitations of a drug-only approach to Alzheimer's treatment.Key topics covered:Why GLP-1s may not be enough for Alzheimer'sThe link between glucose metabolism and brain energy failureHow ketones offer an alternative fuel for the brainEarly research on ketogenic therapy for cognitive impairmentWhy nutritional interventions deserve more scientific attentionWith Alzheimer's affecting millions and costing billions, it's time to shine a light on metabolic strategies that directly support brain energy, reduce inflammation, and improve cognitive function.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Should I take a GLP-1? Real Patient Scenarios and Expert GuidanceTrying to figure out if a GLP-1 medication is right for you can feel overwhelming. With options like Wegovy, Zepbound, Ozempic, and Mounjaro, it's not just about weight—these medications can also support heart health, liver function, sleep, and blood sugar. Understanding who truly benefits takes the guidance of an expert.Joining me today is Danielle Marston, or Dani, a board-certified nurse practitioner specializing in obesity medicine, weight management, and nutrition counseling. Dani holds a certificate of advanced education in obesity medicine through the Obesity Medicine Association and provides comprehensive care at our clinic, Colorado Wake Care at Green Mountain Partners for Health. She's here to explain how GLP-1s work, their benefits, and who they can help the most.Through real patient scenarios and practical advice, Dani shows how obesity care can be personalized, evidence-based, and approachable.Whether you're curious about starting a GLP-1, considering other treatment options, or just trying to understand what's available, this episode gives you a clear roadmap to make informed decisions and find a plan that actually fits your life.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Your Guide to Keeping Blood Sugar in Check A1C Made Simple: Your Guide to Keeping Blood Sugar in CheckFewer meals may prevent Type 2 diabetes, obesityDeep-sleep brain waves are linked to blood sugar controlDrug-Induced Diabetes: Are You at Risk?Popular weight loss drugs Ozempic and Wegovy may cause stomach paralysis, doctors warn https://www.georgebatista.com Spectrum Vibrance: https://collabs.shop/s0emjo The Wellness Company - https://www.twc.health/Batista Wellness Resources - http://www.myvitaminresource.com (Promocode: counterparts - For free shipping) https://rumble.com/user/WellnessTalk https://www.instagram.com/georgebatistajr/ https://open.spotify.com/show/5MvjsMT... https://apple.co/3H39DGK Email:Wellnesstalk@protonmail.com Wellness Resources Since 1985, Wellness Resources has used only the highest quality nutrients, no chemical additives, t Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you. Support the showDisclaimer: The Wellness Talk podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.  

This episode is sponsored by Welbeck - providing beyond better healthcare Today we're getting into the weighty topic of GLP-1 weight-loss drugs. Ozempic, Wegovy, Mounjaro - it's a hot topic with a story in the news about it every week.   We are delighted to be joined by consultant endocrinologist Dr Saira Hameed who cuts through the noise bringing medical facts and who knows this topic inside and out. In this episode Dr Saira is mythbusting and answering all of your questions and ours about weight loss injections. It's a fascinating episode you won't want to miss. In this episode we discuss: The different drugs on offer Who should and should not be taking them Side effects and health risks Who qualifies for NHS treatment Why honesty is imperative  The moral panic and is it “cheating” to take them. To learn more or book an appointment go to: https://onewelbeck.com/consultants/dr-saira-hameed/ To buy her books: https://amzn.eu/d/3FXSB1B      https://amzn.eu/d/bl86fm0 Get 20% off at LondonNootropics.com with the code SELFCARE If you liked this episode and want to be part of the club, come follow us on all our socials:  To Listen To 40ISH - https://podcasts.apple.com/gb/podcast/40ish/id1757876983 To order our book “HAVE YOU TRIED THIS?” click here - Paperback out now!  https://www.amazon.co.uk/Have-You-Tried-This-Only/dp/1801293139/ref=sr_1_2?crid=1O7EA4ZF1O5CS&keywords=have+you+tried+this&qid=1699449028&sprefix=have+you+tried+%2Caps%2C125&sr=8-2 For Our Exclusive Merch - https://self-care-club.myspreadshop.co.uk/ Join Our Private Facebook Group https://www.facebook.com/groups/1115099072702743/?ref=share_group_link Instagram  https://www.instagram.com/selfcareclubpod/ YouTube https://youtube.com/c/SelfCareClub TikTok https://vm.tiktok.com/ZMLnXyS1S/ Email hello@theselfcareclub.co.uk  Website www.theselfcareclub.co.uk Studio production by @launchpodstudios Music by purpleplanet. Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We unpack new GLP-1 pricing, coverage hurdles, and whether cash-pay programs make these meds more reachable for diabetes, obesity, and sleep apnea care. Along the way we share candid pros and cons of injections, tease future oral options, and weigh real tradeoffs.• current cash-pay pricing from major manufacturers• differences between Wegovy, Ozempic, and Zepbound• tighter insurance coverage and prior authorization burden• fears about injections and route-of-administration bias• potential oral GLP-1 timelines and cost impact• framing obesity as a chronic, treatable disease• practical tips to explore HSA or FSA options• how to decide if the monthly cost is worth itSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

If you've been waiting for a GLP-1 weight loss medication that doesn't require injections, special timing, or refrigeration—this episode is for you. Learn about the groundbreaking oral pill that could hit the market as early as 2026. For years, effective obesity medications have meant needles. But Orforglipron could change everything. In this episode, I break down the science, clinical trial results, and approval timeline for this first-of-its-kind once-daily pill that delivers GLP-1 benefits without the injection barriers. Whether you're needle-averse, struggle with injection site reactions, or simply want more convenient options, this new medication could expand access to life-changing obesity treatment.   Episode Highlights: What makes Orforglipron different from Wegovy, Zepbound, and oral semaglutide Clinical trial results: 12.4% average weight loss over 72 weeks Why this oral pill doesn't require fasting or special timing like other oral GLP-1s The FDA accelerated review process and potential 2026 approval timeline Who benefits most: patients with needle phobia, injection site reactions, or seeking maintenance therapy What to expect regarding insurance coverage and access once approved   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Your Guide to Keeping Blood Sugar in Check A1C Made Simple: Your Guide to Keeping Blood Sugar in CheckFewer meals may prevent Type 2 diabetes, obesityDeep-sleep brain waves are linked to blood sugar controlDrug-Induced Diabetes: Are You at Risk?Popular weight loss drugs Ozempic and Wegovy may cause stomach paralysis, doctors warn https://www.georgebatista.com Spectrum Vibrance: https://collabs.shop/s0emjo The Wellness Company - https://www.twc.health/Batista Wellness Resources - http://www.myvitaminresource.com (Promocode: counterparts - For free shipping) https://rumble.com/user/WellnessTalk https://www.instagram.com/georgebatistajr/ https://open.spotify.com/show/5MvjsMT... https://apple.co/3H39DGK Email:Wellnesstalk@protonmail.com Wellness Resources Since 1985, Wellness Resources has used only the highest quality nutrients, no chemical additives, t Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you. Support the showDisclaimer: The Wellness Talk podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.  

The World Health Organisation has updated its guidelines for their treatment of obesity - and is now recommending GLP-1 drugs, like Ozempic and Wegovy, alongside behavioral therapy. University of Auckland's Professor Peter Shepherd spoke to Ingrid Hipkiss.

Opposition leader, Chris Hipkins spoke to Morning Report; The mother of a girl who ate a potentially mouldy school meal is disgusted students were served gone off food; The World Health Organisation has updated its guidelines for their treatment of obesity - and is now recommending GLP-1 drugs, like Ozempic and Wegovy, alongside behavioral therapy; With the country set to miss its Smokefree 2025 target, the government is exploring legalising oral nicotine pouches; For today only, registered charities or schools donated to via Givealittle will receive the full amount, with the crowdfunding site waiving its usual 5% fee.

Écoutez le meilleur de l'émission La commission du lundi 1er décembre 2025: Le gouvernement fédéral envisage-t-il réellement de mettre fin au télétravail à partir de 2027? L’OMS recommande les médicaments comme Wegovy et Ozempic pour lutter contre l’obésité dans le monde; «Limiter le droit de grève, pour nous ça vient brimer le droit d'association» -Robert Comeau; Une casquette à plus de 1000$ chez Costco pour aider à combattre la calvitie. Voir https://www.cogecomedia.com/vie-privee pour notre politique de vie privée

We are excited to host Dr. Jordanna Kapeluto for our November Huddle, where she will unpack the science and real-world impact of GLP-1 and weight loss medications. Dr. Kapeluto will discuss how these medications work, their potential benefits and risks, and what people living with or at risk for Type 1 Diabetes should know before considering them.Over 18 and interested in sharing your experiences living with type 1? Register to attend a live huddle at www.t1dhuddle.com

It's our 100th episode! I celebrate this milestone with Karen Bradley, NP, discussing the biggest wins, most common questions, and key themes from nearly two years of podcasting about women's sexual health and menopause.We dive into the FDA's recent decision to remove the boxed warning from vaginal estrogen a huge victory for women's health advocacy. This warning has prevented countless women from getting treatment for painful sex, recurrent UTIs, and other symptoms of genitourinary syndrome of menopause. I share a powerful story of a patient with breast cancer history who was denied hormone therapy by her oncology team, only to have them completely reverse course once the boxed warning was removed.The conversation covers the most frequently asked questions from listeners: Is it perimenopause or just stress? (It's both.) Why is my libido gone? (Biology, psychology, and life circumstances all play a role.) Why do I keep getting UTIs after sex? (Often it's vestibulodynia or changes in the vaginal microbiome from estrogen deficiency.) How do I talk to my partner about sex? (Communication is key, and sometimes you need a sex therapist to help.)We also discuss the reality of midlife weight gain, the role of GLP-1 medications like Wegovy and Zepbound, and why building muscle matters more than endless cardio. This episode is a celebration of how far we've come and a reminder that you don't have to suffer through menopause.Highlights:The FDA removed the boxed warning from vaginal estrogen—what this means for access to careThe biology behind midlife low libido and why it's not "all in your head"Why recurrent UTIs after sex might actually be vestibulodynia or vaginal microbiome changes.How to talk to your partner about sex when you've never had those conversationsThe truth about midlife weight gain and what hormones can and can't doGLP-1 medications: FDA approvals for weight loss, cardiovascular protection, MASH, and sleep apneaThank you for being here for 100 episodes. Honestly, there have been times I've wanted to stop, but then I get a DM from someone saying they heard something on the podcast that changed their care, or a patient tells me they finally found answers here. That's what keeps me going.The biggest way you can help me keep doing this work is simple: share this show with someone who needs it and hit subscribe. When you share an episode with a friend who's struggling, a family member who's been dismissed by doctors, or post about it on social media, you're helping me reach more women who deserve better care.Thank you for listening, for learning, and for advocating alongside me. Here's to the next 100.Get in Touch with Me: WebsiteInstagramYoutubeSubstack

My granddaughter suffers from menstrual cramps.  Do you have any suggestions?Do you recommend nicotinamide daily to prevent recurrence of basal cell cancers?What works best to lower fibrinogen?I've been on Ozempic for a year and have diarrhea every morning!Is bypass surgery still being done?Would you recommend Bergamot for fatty liver?

Thanksgiving and overindulgenceA food poisoning incidentObservations on health at ThanksgivingWhat do you think of online sites offering prescriptions for hair loss via a questionnaire?

Send us a textIn this week's episode of The Autoimmune RESET Podcast, I'm joined by Nagina Abdullah, founder of MasalaBody.com, molecular biologist, and creator of the “Spice Yourself Skinny” method.Nagina shares her deeply relatable journey — from lifelong struggles with weight, sugar cravings, and yo-yo dieting to discovering the science of metabolism, inflammation, and adding the right foods rather than restricting them. After losing 18kg and keeping it off for 14 years, her story takes an honest midlife twist: perimenopause, bloating, metabolic slowing, and how she rebuilt her health by shifting to an anti-inflammatory, nutrient-dense approach.We explore how spices, whole foods, fibre, and smart carb-protein pairing can completely transform energy, digestion, weight stability, and inflammation — especially for women navigating thyroid issues, Hashimoto's, autoimmune symptoms, and midlife hormone shifts.Inside this conversation, you'll learn:Why chronic under-eating is one of the biggest drivers of sugar cravings, fatigue, gut sluggishness, and metabolic slowdownThe connection between inflammation, nutrient deficiencies, thyroid health, and autoimmune flaresHow spices like turmeric, cinnamon, cumin, and chili can naturally lower blood sugar, reduce inflammation, boost metabolism, and support digestionWhy your body needs carbohydrates — and which carbs actually stabilise weight, energy, and thyroid functionHow to pair protein, fibre, and slow-burning carbs to reduce cravings, support gut health, and keep blood sugar steadyThe truth about GLP-1 medications (Ozempic, Wegovy): who they help, how they can deplete nutrients and muscle mass, and how to naturally support GLP-1 pathways without medicationWhy convenience eating and skipping meals silently drive inflammation and autoimmune symptomsPractical ways to meal-prep with flavour so you stay nourished and never feel restrictedNagina shares her "Sweet Spice Cheat Sheet" with the spice that is in your kitchen cabinet! It helps to lower blood sugar and curb sugar cravings. The cheat sheet includes:3 health benefits of using this spice5 ways to use it in your dayAn easy recipe using this spicehttps://masalabody.com/SweetSpicePDF/Connect with Nagina: https://masalabody.com, instagram.com/masalabodyThis episode is such an empowering reminder that metabolism is not just about weight — it's about nourishment, hormones, blood sugar, inflammation, and the messages your body has been trying to send you.Subscribe to the podcast for more expert insights on healing chronic illness through root-cause medicine, and if you found this episode helpful, leave a review or share it with someone who needs it.The information shared in this episode is for educational purposes only and is not intended to replace medical advice. Always consult your healthcare provider before making changes to your medications, supplements, or treatment plan — especially if you have a diagnosed autoimmune condition.Thanks for listening! You can join The Autoimmune Forum on Facebook or find me on Instagram @theautoimmunitynutritionist.

Dos soldados de la guardia nacional fueron baleados en Washington DC cerca de la Casa Blanca y se encuentran en condición crítica. El sospechoso está bajo custodia de las autoridades. Los inmigrantes indocumentados volverán a tener derecho a fianza.El Departamento de Justicia reconoció que Kristi Noem desacató al orden de un juez federal de suspender los vuelos de deportación hacia El Salvador.Más de 50 millones de personas están bajo alerta por bajas temperaturas y fuertes ráfagas de viento.El empresario mexicano y co propietario de Miss Universo, Raúl Rocha, fue imputado por tráfico de armas, drogas y combustible.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve deep into a series of transformative events that underscore the dynamic nature of our industry, where scientific innovation meets regulatory evolution and market adaptation.We begin with significant regulatory news from Medicare, which recently announced price reductions for 15 prescription drugs, including Novo Nordisk's semaglutide products, Ozempic and Wegovy. This initiative is part of the Inflation Reduction Act aimed at making essential medications more affordable. By potentially increasing accessibility to these treatments, this move highlights a growing trend towards cost containment in drug pricing within the U.S. healthcare system. It reflects a broader effort to ensure that life-saving treatments remain within reach for more patients, emphasizing the need for balance between innovation and affordability.Turning to approvals, Otsuka has secured FDA clearance for Voyxact, a first-in-class treatment targeting IgA nephropathy (IgAN). This positions Otsuka in an increasingly competitive market space populated by major players like Novartis and Vertex. The entry of Voyxact could pave the way for innovative therapeutics in kidney diseases, offering new hope to patients who have had limited treatment options until now.On the other side of the Atlantic, French authorities have conducted a raid on Sanofi's headquarters as part of a tax fraud investigation. This development sheds light on ongoing scrutiny in the pharmaceutical sector regarding financial practices and regulatory compliance. Such investigations can have far-reaching implications on corporate governance and transparency, reminding us of the importance of ethical practices in maintaining industry trust.Novo Nordisk has strategically used its FDA national priority voucher to expedite the review process for a high-dose formulation of Wegovy. This move underscores the importance of regulatory incentives in accelerating drug development timelines, allowing for quicker patient access to potentially life-changing therapies. It's a testament to how strategic navigation through regulatory pathways can significantly impact drug availability.In clinical trials, Sarepta Therapeutics received FDA clearance to conduct a study combining its gene therapy Elevidys with sirolimus in patients with Duchenne muscular dystrophy. The study aims to address liver safety issues associated with Elevidys, which had led to previous label restrictions. This reflects the industry's commitment to enhancing therapeutic safety profiles while expanding treatment indications.In oncology advancements, AstraZeneca's Imfinzi received FDA approval for use in early-stage stomach cancer, marking its third perioperative indication. This approval underscores the expanding role of immunotherapy across various cancer types and stages, offering new treatment paradigms that could improve surgical outcomes and long-term patient survival.Despite these advances, there is skepticism regarding artificial intelligence's role in regulatory compliance submissions among pharmaceutical professionals. A survey reveals that 65% express distrust towards AI-generated outputs, highlighting challenges that AI technologies face in gaining acceptance within highly regulated environments such as pharmaceuticals. However, federal recommendations to revamp U.S. biotechnology research emphasize incorporating AI into scientific processes to maintain global competitiveness. This call reflects concerns over potential declines in innovation leadership and underscores the need for strategic investment in research infrastructure.In antitrust news, the Federal Trade Commission (FTC) outlined its case agaiSupport the show

City Hall is probing the surge in so-called “skinny jabs”, as London Assembly members warn of unlicensed sellers, counterfeit pens and off-label prescriptions. The hearing digs into how Londoners are accessing GLP-1 drugs like Wegovy and Mounjaro — and whether people are being properly protected and informed.The Environment Agency has released new bathing-water rankings, showing a slight improvement across England's coasts and lakes — but river sites are still performing badly, with only two out of fourteen meeting basic standards. Plus, a landmark study in Wales has mapped its most threatened species, revealing around 3,000 plants and animals surviving in just a handful of locations. Also in this episode:UK firm Lacuna Space prepares to launch four new “Wisdom of the Trail” satellites to connect remote sensors directly to orbit.Tokyo astronomers report a potentially promising dark-matter signal in 15 years of Fermi telescope data.Fujitsu unveils an “ocean digital twin” to speed up certification of blue-carbon projects.Saudi Arabia's PIF faces scrutiny over finances amid its $55bn deal to buy EA.Battlefield 6 launches its free trial via Redsec, unlocking three playlists and maps until 2 December. Hosted on Acast. See acast.com/privacy for more information.

This episode of The Food Professor Podcast takes a deep dive into one of the most powerful forces now reshaping the food industry: the rapid rise of GLP-1 weight-loss drugs such as Ozempic and Wegovy. Hosts Michael LeBlanc and Dr. Sylvain Charlebois begin with a run-through of current food and retail headlines, including controversy at Campbell Soup, conversations around AI adoption and innovation in the food sector, and early teasers from the 2026 Canada Food Price Report. These stories set the stage for this week's feature discussion: how GLP-1 medications are altering what consumers eat, where they shop, and which products they choose.The heart of the episode features an in-depth interview with Ransom Hawley, Founder and CEO of Caddle, a Canadian mobile-first consumer insights platform with access to real-time behavioural data. Hawley shares new Canadian research showing GLP-1 household usage has jumped from 10% to 14% over two years, a dramatic 40% increase. Equally important is the shift in why people are taking these drugs: where most users initially relied on them to manage type-2 diabetes, an increasing number now use them primarily for weight loss. That consumer pivot mirrors rapid adoption trends in the United States and offers important clues about what's coming next for Canadian retailers, manufacturers and restaurants.Hawley reveals that GLP-1 users report eating less, losing weight, buying fewer groceries, and reducing restaurant visits. Consumption of alcohol, sugary beverages and impulse-driven snack foods is falling, while protein-rich foods, functional beverages and satiety-oriented products are gaining momentum. Categories seeing the steepest declines include bakery goods, packaged cookies, chocolates, soft drinks and sweet snacks—all long-time staples of convenience-driven food consumption. This suggests a structural shift, not a temporary fad.The conversation expands to consider the broader implications. As GLP-1 usage rises, brands face new challenges and opportunities: How should they reformulate products for consumers who eat less? Should retailers redesign planograms to reflect category shrinkage? Will foodservice operators pivot toward protein-forward meals, smoothies and portion-smart menu strategies? As the hosts discuss, this is the first time since COVID-era lockdowns that such a large segment of the population is simultaneously changing eating behaviours, and its ripple effects will reshape category strategies, promotional plans, and innovation pipelines.By the end of the episode, one thing is clear: GLP-1 drugs are not just a pharmaceutical phenomenon—they are transforming food culture, retail economics, and consumer expectations. Retailers and brands that ignore this shift risk falling behind; those who understand it may unlock a once-in-a-generation competitive advantage. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Medicare will get a 71% discount off the list price of Ozempic and Wegovy starting in 2027. That will bring the monthly costs of those drugs down from nearly $1,000 to $274. The Centers for Medicare and Medicaid Services also announced price reductions for 14 other drugs. We'll hear more. Plus, can a market economy that uses fake cash help food banks get the food donations they want?

Medicare will get a 71% discount off the list price of Ozempic and Wegovy starting in 2027. That will bring the monthly costs of those drugs down from nearly $1,000 to $274. The Centers for Medicare and Medicaid Services also announced price reductions for 14 other drugs. We'll hear more. Plus, can a market economy that uses fake cash help food banks get the food donations they want?

Rough Week – does not phase bulls! Bitcoin – Bottoming? Let’s take a look at Walmart and Target again Homeowners! Mortgage Reform? PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Short Week - Markets closed on Thursday and short Friday (1pm) - Can't have a down week for TDAY! - Too much table talk - Recession News - Let's take a look at Walmart and Target again - Homeowners! Mortgage Reform? Markets - Rough Week - does not phase bulls! - Bitcoin - Bottoming? - NVDA - China Bound? - NASDAQ Weighting Inflation - Still Up There - They are now pressing for a cut in December (How are we handicapping this?) - All of a sudden the parade of Fed speakers - all seem a bit more dovish. Meanwhile - President Donald Trump on Friday rolled back tariffs on more than 200 food products, including such staples as coffee, beef, bananas and orange juice, in the face of growing angst among American consumers about the high cost of groceries. - oranges, acai berries and paprika to cocoa, chemicals used in food production, fertilizers and even communion wafers. Quantum Stocks GOOD NEWS! - NO Recession risk! - Bessent says inflation due to services economy, not tariffs - Treasury secretary says Republicans should end filibuster in event of another shutdown - Bessent says administration working to lower prices where it can - Banking and insurance,  Software development and cloud services, Tourism, Restaurants and hospitality , Professional services (law, accounting, consulting) Rigging it - NEC Director Kevin Hassett emerges as frontrunner for Fed Chair as President Trump nears decision, according to Bloomberg Weird News - Buried in the NVDA earnings report - Remember back in September, the two companies announced a massive partnership that would include a $100 billion investment over time by Nvidia into OpenAI. - Nvidia said in its quarterly financial filing that there's no guarantee that the company will finalize an agreement with OpenAI. - Soooooo - is this all hot air???? More NVDA - Here we go. Another reversal - President Donald Trump will make a final decision on whether to allow Nvidia Corp. to sell advanced artificial intelligence chips to China. - The decision involves weighing the promotion of economic expansion against protecting national security, according to US Commerce Secretary Howard Lutnick. ------ Read that again - money versus national security - Allowing the sales would mark a significant easing of restrictions imposed in 2022 to prevent Beijing and its military from accessing the most powerful US technologies. Chip in question: H200 - Had some discussions about this - might as well as they will just get it on their own and this way we can control. (On the other hand, they have a long history of outsmarting us) EVEN MORE - NVIDIA issues memo to CNBC: The company said "We are not aware of any claims that NVDA has improperly capitalized operating expenses. Several commentators allege that customers have overstated earnings by extending GPU depreciation schedules beyond economic useful life" | - The tip of the Iceberg - this is what Michael Burry has been pressing..... HPQ Earnings - HP Inc. beats by $0.01, reports revs in-line; guides Q1 EPS in-line; guides FY26 EPS below consensus; increases dividend; announces company-wide initiative, includes job cuts - Stock down 6% Amazon - The Spend keeps going... - Amazon.com Inc. says it will spend as much as $50 billion expanding its capacity to provide artificial intelligence and high-performance computing services to US government entities. - Amazon Web Services plans to break ground next year on what will ultimately be 1.3 gigawatts of additional capacity across data centers designed for federal agencies, the company said in a blog post on Monday. Google/Berkshire - Berkshire Hathaway revealed a $4.3 billion stake in Google parent Alphabet (GOOGL.O), further reduced its stake in Apple - Google on a ramp since - new Gemini and... - Meta Platforms Inc. is in talks to spend billions on Google's AI chips, adding to a months long share rally as the search giant has made the case it can rival Nvidia Corp. as a leader in artificial intelligence technology. - Meta is in discussions to use the Google chips — known as tensor processing units, or TPUs — in data centers in 2027, and may rent chips from Google's cloud division next year. - Really smart people at Berkshire? What did they know? NASDAQ 100 - Uninvestable? - Top 10 stocks are over 70% weighting - SP500 top 10 stocks = 38% - This is not a diversified approach any longer - Coming up on next week's TDI Podcast - Howard Silverblatt - S&P Dow Jones - Keeper of the data Something They Don't Want You To Know - “Magnificent 7” Companies Reported Lowest Earnings Growth Since Q1 2023 - With NVIDIA reporting actual results for Q3 on November 19, all the companies in the “Magnificent 7” have now reported earnings for the third quarter. - “Magnificent 7” companies reported actual earnings growth of 18.4% for the third quarter. This earnings growth rate is below the average earnings growth rate of 28.8% for these seven companies over the previous four quarters. Novo Nordisk - Pummeled - Shares of Novo Nordisk on Monday fell to a four-year low after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's disease failed to meet its main goal. - The trial tested whether semaglutide — the active ingredient in Novo's blockbuster diabetes and weight loss drugs Ozempic and Wegovy — helped slow progression for Alzheimer's disease. -While treatment with semaglutide resulted in improvement of Alzheimer's disease-related biomarkers in two separate trials, this did not translate into a delay of disease progression, Novo said in a statement Monday. The goal had been to slow patients' cognitive decline by at least 20%. - Reminiscent of Pfizer - after Covid shot had noting left... Bitcoin - Live by the sword.... - iShares Bitcoin Trust had $2.2 billion in net outflows in November, according to WSJ - Big month of losses for crypto - not too much mention and support by Whitehouse - Selling started - coincidentally with  the pardon of Changpeng Zhao, the convicted founder of the Binance Remember DOGE - DOGE disbanded eight months ahead of scheduled end in July 2026 - Former DOGE employees take new roles in administration - Elon Musk initially led DOGE, promoting its work on social media - bagged out when stock tanked - DOGE claimed to have slashed tens of billions of dollars in expenditures, but it was impossible for outside financial experts to verify that because the unit did not provide detailed public accounting of its work. Walmart - Walmart raised its sales and earnings outlook last week as the retailer posted revenue gains in its fiscal third quarter, driven by double-digit e-commerce growth and new customers across incomes. - The retailer said it expects full-year net sales to climb between 4.8% and 5.1%, up from its previous expectations of 3.75% to 4.75%. - It said it expects its adjusted earnings per share to range from $2.58 to $2.63, a slight raise from its prior range of $2.52 to $2.62. - Stock went vertical ---- - Much different story than Target - WMT up 16% YTD - TGT down 37% Beef Prices - Not Going Down - Tyson Foods stock rallying on Monday following the company's official confirmation that it will shutter its Lexington, Nebraska, beef facility, a strategic move that validates earlier reporting by The Wall Street Journal. - The decision comes as the meat and poultry giant grapples with historically low U.S. cattle inventories, which have severely compressed margins and led to a reported $426 mln adjusted operating loss for its beef segment in FY25.| - Seems that investors like this decisive cost-cutting measure, viewing the capacity reduction as a necessary step toward restoring profitability in a challenging commodity environment. Japan - Japanese Prime Minister Sanae Takaichi's cabinet approved a 21.3 trillion yen ($135.40 billion) economic stimulus package last Friday, marking the first major policy initiative under the new leader, who has pledged to pursue expansionary fiscal measures. - The package includes general account outlays of 17.7 trillion yen, far exceeding the previous year's 13.9 trillion yen and representing the largest stimulus since the COVID pandemic. It will also include 2.7 trillion yen in tax cuts. - Problem is that the Yen is sliding and intervention is imminent - Inflation issue and they will make it worse with this stimulus Larry Summers? - Epstein Files - IS there any There , There? Talk about a 50 Year Mortgage? - Such a bad idea  - and these boneheads think it is smart - 30-Year Mortgage Monthly Payment: $1,610.46 Total Payment: $579,767.35 Total Interest Paid: $279,767.35 - 50-Year Mortgage Monthly Payment: $1,362.42 Total Payment: $817,449.78 Total Interest Paid: $517,449.78 Thanksgiving Costs 2025 National Average (American Farm Bureau Survey) - 2025: $55.18 for a classic dinner for 10 people (about $5.52 per person) - 2024: $58.08 for the same meal - Change: Down 5% year-over-year This is the third consecutive annual decline since the record high of $64.05 in 2022. Key Drivers Turkey prices dropped sharply: A 16-pound frozen turkey averages $21.50, down 16% from 2024. Sides are mixed: Dinner rolls and stuffing are cheaper (down 14.6% and 9%). Sweet potatoes and veggie trays are much higher (up 37% and 61%). Regional Differences South: $50.01 (most affordable) West: $61.75 (most expensive) Classic Meal for 10 ($55???????) 16-pound turkey (frozen, whole) Stuffing mix (14 ounces) Sweet potatoes (3 pounds) Rolls (12-count package) Peas (1 pound) Cranberries (12 ounces) Carrots and celery (for a veggie tray) Pumpkin pie mix (30 ounces) Pie shells (two, 9-inch) Whipping cream (half pint) Milk (1 gallon) - Love the Show? Then how about a Donation? THE CTP FOR: iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Summary del Show: • Los futuros de EE.UU. suben con el optimismo de nuevos recortes de tasas tras datos de inflación y consumo más suaves. • Foxconn $AAPL $NVDA invertirá $569M en IA en Wisconsin, creando más de 1,300 empleos. • Uber $UBER y WeRide $WRD inician servicio comercial de robotaxis en Abu Dhabi, el primero en Medio Oriente. • Trump anuncia acuerdo histórico para reducir 71% el costo de 15 fármacos bajo Medicare, incluyendo Ozempic y Wegovy.

In this fun, laugh-filled and genuinely eye-opening episode, Michelle Ford sits down with women's health nutritionist Emma Bardwell to tackle one of the most underrated pillars of midlife wellbeing: fibre - the true unsung hero of women's health. Between giggles over “poophoria” (yes, it's a thing!) and some serious myth-busting, Michelle and Emma unpack why getting enough fibre and protein is essential - especially if you're using GLP-1 weight-loss injections like Ozempic, Wegovy or Mounjaro. As Emma explains, these medications slow digestion, making fibre even more important for gut motility, nutrient absorption and long-term health.Forget fibre's dusty, boring reputation - this episode gives it a full glow-up. Through perimenopause and menopause, when hormones fluctuate and the gut becomes increasingly linked to mood, energy and resilience, fibre becomes a midlife powerhouse. Michelle and Emma explore how nourishing your gut supports immunity, mental wellbeing, metabolism and overall vitality, and why our midlife microbiome deserves centre stage. With Emma's straight-talking, practical approach, you'll learn simple, everyday ways to boost your fibre intake - no chia-seed obsession required.By the end, you'll never look at your plate (or your bowel movements!) the same way again.

New weight loss drugs may portend end of “Fat Acceptance” movement; Celebs and Southerners embrace GLP-1s; Trump clears path for more access to diet drugs; Mid- and late-life exercise slash dementia risk; “Ethicists” urge more tick-borne meat allergy to save planet—as alpha-gal syndrome claims first fatality; What's wrong with the melatonin study that claims it leads to heart failure? How to detox 9-11 first-responders? Can weekend warriors obtain same benefits as regular exercisers? 

In this conversation, Gianna discusses the role of GLP-1 medications in weight management, emphasizing that they are tools to support individuals in their health journeys rather than shortcuts. She highlights the importance of building habits and how GLP-1s can reduce resistance in the body, making it easier to achieve health goals.TakeawaysGLP-1s are tools that enhance the effectiveness of your efforts.They help build habits without constant struggle.The use of GLP-1s is not a shortcut but a strategic change.They support the body's processes to function more easily.Feeling your best is achievable with the right support.Weight management requires personal effort alongside medication.GLP-1s can reduce friction in health journeys.Building habits is crucial for long-term success.The relief of effective strategies can be rewarding.Support from GLP-1s can lead to better health outcomes.

In this episode, Dr. Taves and Dr. Sarah Thomas explore how GLP-1 weight loss drugs—such as Ozempic, Wegovy, and Mounjaro—may influence headaches and migraines. They break down how these medications work in the body, how blood sugar stability impacts migraine symptoms, and why some people notice improvement while others experience worsening headaches.They also discuss an important but often overlooked consideration: even if GLP-1 medications help with weight loss or migraine symptoms, there may be other factors to think about before relying on them long-term. From side effects to the difference between symptom management and addressing the root cause, this episode helps listeners understand the full picture so they can make informed decisions.Novera: Headache Center

Novo Nordisk, leader européen de la pharma en 2023, a vu sa capitalisation chuter de 63 % en deux ans, dépassé par Eli Lilly et son Mounjaro. La concurrence s'intensifie sur le marché des traitements contre l'obésité, avec l'arrivée attendue de nouveaux acteurs comme Roche et Pfizer. Dans « La Story », le podcast d'actualité des « Echos », Pierrick Fay et Myriam Chauvot reviennent sur la bataille de l'obésité dans l'industrie pharmaceutique, bataille arbitrée aussi par Donald Trump.« La Story » est un podcast des « Echos » présenté par Pierrick Fay. Cet épisode a été enregistré en novembre 2025. Rédaction en chef : Clémence Lemaistre. Invitée : Myriam Chauvot (journaliste au service industries des « Echos »). Réalisation : Willy Ganne. Musique : Théo Boulenger. Identité graphique : Upian. Photo : Shutterstock. Sons : BFM Business, Loopsider, extrait « La cité de la peur », extrait «L'aile ou la cuisse», Extrait «Taxi 3». Retrouvez l'essentiel de l'actualité économique grâce à notre offre d'abonnement Access : abonnement.lesechos.fr/lastory Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Hey friends!

„Wir leben in einer Zeit, in der viele nach schnellen Lösungen suchen. Aber bevor wir über die Abnehmspritze urteilen, müssen wir genau verstehen, was sie im Körper macht, für wen sie sinnvoll ist – und wo ihre Grenzen liegen.“ Dr. Thomas Kurscheid ist Facharzt für Allgemeinmedizin, Ernährungs- und Sportmediziner, erfolgreicher Buchautor und Leiter des Adipositaszentrums Köln. Seit Jahren begleitet er Patientinnen und Patienten, die mit klassischem Abnehmen an ihre Grenzen stoßen – und kennt Chancen und Risiken der neuen GLP-1-Medikamente wie kaum ein anderer. In dieser Folge BUNTE VIP GLOSS spricht Podcast-Host Jennifer Knäble mit dem Experten über das Thema, das derzeit die Gesundheits- und Beautywelt bewegt: Abnehmspritzen wie Wegovy und Ozempic. Dr. Kurscheid erklärt , wie die Wirkstoffe Appetit und Essverhalten beeinflussen, warum emotionales Essen dabei eine zentrale Rolle spielt – und weshalb die Medikamente Menschen mit echter Adipositas helfen können, aus dem jahrelangen Teufelskreis aus Diäten, Frust und Gewichtszunahme auszubrechen. Er räumt mit Mythen auf und ordnet ein: – Ozempic und Wegovy sind strikt getrennte Präparate für Diabetes bzw. Adipositas. – Das sogenannte „Ozempic Face“ ist kein Medikamenteneffekt, sondern die Folge schnellen Gewichtsverlusts. – GLP-1 wirkt zuverlässig – aber nur solange man es nimmt. Der Jo-Jo-Effekt nach dem Absetzen ist vorprogrammiert. – Die Therapie muss medizinisch begleitet werden: regelmäßige Kontrollen, Labordiagnostik, psychologische Unterstützung und klare Ernährungsempfehlungen. Dr. Kurscheid erklärt den Unterschied zu ästhetischen Behandlungen wie der Fettwegspritze, spricht über Alternativen wie Ernährungsprogramme und Kryolipolyse und zeigt, warum viele Menschen trotz großer Motivation ohne professionelle Hilfe nicht aus hormonellen und verhaltensbedingten Mustern herauskommen. Jenny fragt nach Risiken, Kosten und Zukunft: Wie sicher sind GLP-1-Medikamente bei Vorerkrankungen? Was bedeuten monatliche Kosten von 170 bis 490 Euro realistisch? Und welche Rolle spielen neue, günstigere Generika wie Liraglutid? Fazit des Gesprächs: Die Abnehmspritze kann ein starkes medizinisches Werkzeug sein – aber nur mit Begleitung, Verantwortung und dem Verständnis, dass sie kein Lifestyle-Produkt, sondern eine Therapie ist. Dr. Thomas Kurscheid bei BUNTE VIP GLOSS. – Hier findet ihr alle Informationen zu unseren Podcast-Partnern: https://www.wonderlink.de/@buntevipgloss-partner Ein BUNTE Original Podcast.

What happens when 12% of US adults start using weight loss medication that suppresses their appetite? We're finding out in real time - and the food industry is working to respond.  In this episode of the Food Matters Live podcast, recorded at our event in Dublin in November 2025, we look at how GLP-1 drugs like Ozempic and Wegovy are already leading to retailers and manufacturers all over the world fundamentally rethinking their strategies. The numbers are stark: households using GLP-1s spend 6% less on food overall, meanwhile, protein yogurts, meat snacks, nutrition bars and fresh produce are thriving as users seek nutrient-dense foods to maintain nutrition while eating far less. GLP-1 isn't a side story, in fact, this consumer segment is already the same size as the vegan/vegetarian market in the UK. And the signs are that it's only going to grow. The real challenge is, we don't know if users will take these drugs once, multiple times in cycles, or continuously at maintenance doses - and each scenario requires completely different food industry responses.

Hey friends!

Ozempic. Wegovy. Mounjaro. If you've ever found yourself wondering, “Should I try one?”—this episode is for you.Roughly 12% of Americans have tried a weight loss drug, yet up to 85% stop within two years. Most regain the weight, and many feel worse than before. So why do these drugs seem so promising—and why don't they work long-term?Today you will learn…- How GLP-1 drugs actually work - The dark side of GLP-1s that no one mentions- What happens when you stop taking weight loss medications - The sustainable alternative to healing food noise

You've done the meal prep, the steps, the Peloton rides after bedtime stories—yet the scale is not "scaling". Now everybody from your group chat to Serena Williams is talking about “the shot.” In this episode, Dr. Stephane Hack, MD, MPH, breaks down GLP-1 medications (like Ozempic, Wegovy, and Zepbound) in plain language: what they are, how they work, who they're really for, and what risks often get glossed over. We'll talk motherhood, metabolism, perimenopause, endometriosis, fertility, and the pressure to “snap back". Whether you're a busy professional juggling work, marriage, kids, or just trying to feel at home in your own body again, this conversation is your judgment-free zone to get informed before you decide what's next for your body.

PODCAST LAS NOTICIAS CON CALLE DE 18 DE NOVIEMBRE 2025 - Saqueo de barcaza a PR fue desde el miércoles pasado - Cuarto Poder  Epstein sería firmado por Trump dice Casa Blanca - Politico Último día de sesión legislativa - El Vocero Se estremece el mercado mundial y la bolsa de valores, Suben sueldo de empleados de corrección a 3 mil mensuales - El Vocero 2 millones cuesta el boquete del superacueducto - El Vocero Reforma contributiva para el 2026 dicen legisladores del PNP que dicen estar contra una Extraordinaria - El Vocero ICE dice que llevará más personal de seguridad a operativos migratorios - El Vocero ONU acepta plan de paz de Trump para Gaza, Israel y Egipto ayudarán a la policía Palestina - PBS Bajan precio de Ozempic y Wegovy a 349 y a 199 para primeros pacientes por dos meses - AxiosCállate puerquita le dice Trump a periodista - CNNA los federales Rodz Veve por filtraciones de Procuradora de la Mujer - El Vocero Redefinen lo que debe ser un fondo de ley 60 para que realmente genere inversión en PR - El Vocero El papá de LUMA llega a PR - El Nuevo Día LUMA dice que va a duplicar empleados, bueno, sus dueños - El Nuevo Día Todavía no han terminado de liquidar a Integrand y Real Legacy - El Nuevo Día Quedan reclamaciones de seguros del huracán María todavía en los tribunales - El Nuevo Día Otra vez paralizado el caso del Horned Dorset por ley de quiebras - El Nuevo Día No hay casas para vender y los precios siguen en históricos 227 mil - El Nuevo Día Recuerdan a Karla Michelle y piden ni una bala más al aire - Primera HoraLa Junta dice que PR necesita supervisión o volverán al déficit - Metro En problemas el Bitcoin bajando a 91 mil USA venderá a Arabia F-35 aunque inteligencia advierte que eso ayuda a China - Fox News Incluye auspicio 

This week, I'm diving into a fascinating piece of research I spotted in The Week; a meta-analysis of 82 studies from University College London looking at how physical activity affects menstrual pain and PMS. The findings are striking: women who move less have a 67% higher risk of painful periods and a 22% higher risk of PMS symptoms.But this episode isn't just about the data, it's about how it intersects with real life. I'm sharing my own PCOS story, from being diagnosed at 17 and barely moving, to being 47, active, and experiencing far fewer symptoms. We'll also unpack the confused (and sometimes misleading) world of cycle-syncing advice online, including what's genuinely helpful and what's been oversimplified by social media.Plus, I'm talking about the growing role of GLP-1 medications like Ozempic and Wegovy: where they can fit into women's hormonal and metabolic health, and why it's not a choice between medication or movement. For many women, the two work beautifully together.Whether you experience period pain, PMS, PCOS, or you're simply curious about how movement and hormones overlap, this episode is all about giving you tools, not rules. Think of it as a realistic, compassionate look at women's health, packed with evidence, lived experience, and nuance.In this episode:The UCL study linking activity levels to menstrual pain and PMSMy PCOS journey: 17 vs 47What cycle syncing gets right, and very, very wrongWhy influencers and experts like Dr Stacy Sims and Dr Vonda Wright create both empowerment and confusionHow exercise supports hormones, mood, metabolism, and overall cycle healthA realistic approach to training across the menstrual cycleWhere GLP-1 medications fit into the pictureWhy movement is a powerful tool but never the only one.Hey! Why not share your thoughts and insights to make your listening experience even better. Complete this listener survey to tell me what you want to hear: http://bit.ly/theemmagunsshow-survey Hosted on Acast. See acast.com/privacy for more information.

Het Exclusive OTP Discounts! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, you will learn:What are peptides? The basic science of these "small proteins" and how they signal cells to function.GLP-1s Explained: How drugs like Ozempic and Mounjaro were originally developed for diabetes but have gained popularity for weight loss.The Big Picture: Peptides are used for more than just weight loss—Dr. Jones discusses their use in migraines, bone building, and studies for ALS and MS.The Weight Loss Surge: Why obesity and its link to chronic diseases (diabetes, hypertension, high cholesterol) is fueling interest in these drugs.The Critical Component: Why a GLP-1 shot is not enough—the medication must be combined with good nutrition, exercise, and psychological health for lasting success.Protein is Key: The importance of adequate protein intake and strength training to maintain muscle mass and prevent hair loss associated with rapid weight loss.The Inflammation Link: How GLP-1s can decrease inflammation (like high cortisol) which often causes stubborn abdominal fat and joint pain.Dispelling Myths: Separating real side effects (like minor hypoglycemia) from media fear-mongering (like blindness), and understanding that hair loss is often due to rapid weight loss, not the drug itself.Next Steps: Where to start if you are interested in peptide therapy and the importance of a consult with a pharmacist.Resources Mentioned:Your Health Wellness Team: Contact the team to schedule a consultation on weight loss goals and peptide therapy. www.YourHealth.Org

El presidente Trump dijo que está dispuesto a dialogar con el gobernante de Venezuela: Nicolás Maduro, luego de que el Departamento de Estado anunciara que se prepara para designar al 'Cartel de los Soles'  como una organización terrorista extranjera.En otras noticias: Charlotte, Carolina del Norte, fue escenario de varios operativos de migración por parte de la patrulla fronteriza. Mas de 130 personas fueron arrestadas.Así mismo en un club nocturno en San Antonio, Texas arrestaron a 140 indocumentados entre los que se encontrarían menores de edad y miembros del 'Tren de Aragua' según las autoridades.El presidente Trump dijo que autorizará la publicación de los archivos Epstein. 

En este episodio analizamos un inicio de semana tenso para Wall Street, marcado por temores sobre deuda corporativa, caída en activos de riesgo y señales de desaceleración económica:

Milk production is up 4.2% year over year, components are climbing and prices are falling. As holiday orders wrap up and we head into the long winter, The Milk Check team digs into whether dairy markets have already found a floor, or if there's still another leg down to go. With milk products everywhere (except for whey), the Jacoby team shares where the market is and where we're going. They churn through: Butter at $1.50 and what heavy cream and higher components mean after the holidays Why cheese feels like a calm before the storm, and how far Class III could grind lower Nonfat and skim: long milk, growing inventories and buyers shopping the cheapest origin Why whey proteins are the outlier, with tight supply, strong demand and GLP-1 tailwinds Global milk growth, clustered demand (Ramadan, Chinese New Year, Super Bowl) and who blinks first between the U.S. and Europe In this episode of The Milk Check, host Ted Jacoby III is joined by Joe Maixner, Jacob Menge, Diego Carvallo, Josh White and Mike Brown for a rapid-fire market session on butter, cheese, nonfat and proteins. Listen now for The Milk Check's latest market read on butter, cheese, nonfat and whey. Got questions? We'd love to hear them. Submit below, and we might answer it on the show. Ask The Milk Check Ted Jacoby III: Welcome back, everybody, to The Milk Check podcast. Today we’re gonna have a market discussion. It is November 10th. We are in the last couple of weeks of the quote-unquote busy season, starting to get a feel for what we think is gonna happen to dairy markets as holiday orders are filled, and we transition into the long-term period of the year. In the last few weeks, we’ve actually seen prices drop, but it feels like butter’s kind of dropped down to about a $1.50/lb and seems to find at least a brief floor. We’ll talk to Joe and find out if Joe thinks we’re gonna stick around here for a while. The cheese market was up in the $1.80s/lb. It’s dropped to a little below $1.70, starting to hit a little bit of resistance. Jake will share with us a little bit about what we think is happening with cheese going forward. Nonfat dropped a little bit down to [00:01:00], about what Diego, about a $1.10/lb and had a little bounce off its floor. Meanwhile, the whey complex just continues to go up. We’ll check in with Josh and find out what’s going on there. Well, let’s go ahead and start with milk production. We just got released today, the September milk production, and it says it’s up 4.2%, which is a very, very big number. It’s November; milk is longer than it usually is this time of year. Usually, it’s quite tight, and it’s not quite tight, but I wouldn’t call it long. However, all the signs are there that once we get past the fall holiday order season, milk could get quite long. If September milk is up 4.2%, I think it’s safe to say that if that continues, we will be quite long milk as we transition from the typical seasonal tightness of the fall into the winter and the flush of the spring. 4.2% is a big number, and that’s not even taking into account the fact that the solids in the milk are up as well. That’s not the kind of tone that a dairy farmer wants us to set as we’re talking about what supply and demand looks like, but there’s a lot of milk out there, [00:02:00] Joe, does that mean there’s a lot of butter out there, too? Joe Maixner: Well, there’s still a lot of butter out there; sounds like there’s going to be a lot more butter coming soon. If milk’s up 4%, cream was heavy all of last winter and into last Spring, extremely heavy. If we have higher components, more milk, and we’ve got a full amount of milk coming outta California as well after coming off of bird flu last year, there’s just gonna be that much more cream in the system and more getting pushed back into the churns. So, it’s a very good possibility that we’re gonna go even lower than where we currently are. Volume seems to be trading well. The cream demand has been fairly steady, going into cultured products and the shorter shelf-life products. Cream’s still long, but it’s not swimming yet. Ted Jacoby III: Will we hold this $1.50 area through Thanksgiving, you think? Joe Maixner: Yeah, it seems like we’ve hit a spot where buyers are willing to step in. So, there’s a good chance that we could hang around this $1.50 area for the next couple of weeks. Once the last little spurt of holiday demand is over, we’re gonna take another leg lower. Ted Jacoby III: Okay. Jake, what about [00:03:00] cheese? Jacob Menge: I think we had a little reprieve from some cheese bearishness with the holiday demand. It’s tough, though, especially with this wall of milk that’s headed our way. Does it seem like the bottom’s ready to drop out? Probably not yet. But it still seems like it’s a possibility. It almost seems like the call before the storm. Ted Jacoby III: What you’re saying is: we’ve already dropped quite a bit, but we’re in typical low points, but it’s possible, considering the amount of supply coming our way, that there’s still another cliff to negotiate, and we could go a lot lower when it comes to Class III milk and cheese prices. Jacob Menge: If you zoom out a ways, going back to mid-2022, we’ve really not liked to go below that $1.55 level on futures. We’re kind of at another support level at this $1.65. Those seem like our two support areas, historically, for the last 3, 4 years. So, it’s probably gonna be one of those grinds lower if we move lower from here, versus that $1.85 to $1.65 was almost an air pocket drop. [00:04:00] It seems like the market’s gonna have to earn it if it moves lower from here, but it does seem like a possibility. Ted Jacoby III: When we get down to these levels, this usually tends to form the floor, and if we have so much cheese out there and so much milk out there that we’re gonna go lower from here, it’s probably not an air pocket drop; it’s probably a grind lower from here. Jacob Menge: Yeah, I think our lows, on the futures, for the past 4 years have been that $1.55. Don’t quote me on that, gimme a couple of cents on either side of that. But that means we got a dime from here to hit those five-year lows, you know, besides COVID. There’s a lot to be said for technical trading at those levels. So, it would take a big fundamental kind of wave supply to get us to crack that. Ted Jacoby III: Got it. Thank you. Diego. What about nonfat? What’s the international market doing? We know we have a lot of milk in North America. We have a lot of milk everywhere. And what does it mean? Diego Carvallo: Customers are also seeing the data, and it seems like they’re in no rush to buy nonfat. Right. Nonfat seems to be the product that is 00:05:00 consistently available. We haven’t seen a very tight market in several years. So, it seems customers are more concerned about other products like WPCs or maybe cheese, other products besides nonfat. So, they’re staying very hand-to-mouth. They’re being very flexible when it comes to origin and just buying spot and from the origin that offers them the cheapest skim milk powder delivered price, which, in most cases, for the past few months, has been either European or New Zealand product because of the shipment time, transit time, and tariffs. Ted Jacoby III: Has the inventory in the U.S. been building as a result? Diego Carvallo: Yes, it has, Ted. Yep. Inventory has been building. I was looking into the milk production numbers for September. California was relatively stable compared to the previous year. I think we grew by 2.5% versus the previous year. But the strong impact from avian [00:06:00] influenza was actually in October. So, that’s when we might see a big jump between California production for 2024 and California production for 2025. So, I thought the Milk Report was pretty bearish for nonfat. Next month could be as bearish or even more. I still believe that we’re gonna see a lot of product going into the dryers, and that’s gonna add pressure, and that’s gonna increase inventories for U.S. products. Ted Jacoby III: What does milk production look like in Europe? Diego Carvallo: They’re actually up quite a bit. I think their September number was also stronger than expected. I can’t recall the exact number, but it was stronger than expected, even though they have cut down on the farmer price, the FrieslandCampina, which is the number one benchmark. It still seems like, with corn moving lower, there’s still a number that incentivizes more milk production. For the next few months until we see a stronger cotton price, we’re gonna see plenty of milk from the U.S. and from Europe. Ted Jacoby III: [00:07:00] Okay, thanks. Appreciate it, Diego. Josh, so what about the protein market? Josh White: Yeah, same story. I don’t know why everybody else is having so many problems with their products because whey proteins are in demand and it continues to be very strong. WPC 80, WPI demand is outpacing supply. People are trying to book forward and can’t. By all reports, the demand on the consumer level remains pretty good. It’s a bit of an outlier. It’s definitely a mystery. A lot of the discussion centers around GLP-1 adoption in the U.S. Compared to a year ago, I think I read this morning, something like 12% of Americans are allegedly using GLP-1-related drugs for weight loss. Assuming that’s an accurate statistic, that’s a noteworthy number of people. There was a lot of discussion last year that as people come on things like Wegovy and Ozempic, at what moment do we mature to the point that people beginning their cycles of taking the drugs equal those coming off of those drugs? There’s just been a lot of headlines about more affordable access to these types of products. If that continues, that shifts this curve even a little bit further up. [00:08:00] What can reverse that trend or slow down the demand for the whey protein side? I think it takes a production response. I can imagine that any manufacturer that’s making whey-related products as a byproduct of their cheese production is exploring how to access this demand, in particular, the whey protein isolate demand. I don’t have the impression that equipment is any easier to get, and there are still plenty of obstacles in terms of making production changes at the processor side. It feels to me like at least through the first half of this year, we’re gonna continue to be under-supplied relative to the demand that’s out there. And I think it’s important to note that although we’re talking about good demand for these products, the GLP-1-related impact on the dairy market isn’t all positive. It’s certainly a positive on the whey protein side. Still, I think, as it relates to consumer demand for butterfat, cheese products, and some of the other snack foods that dairy products are used in, in the CPG space, people are consuming fewer calories. Throughout the rest of the world, this health and wellness [00:09:00] trend and this appetite for quality protein are everywhere. Their demand continues to be very strong internationally. Maybe a couple of other things that are noteworthy, maybe early indicators of the price stabilizing, it looks like Europe and the U.S. might be closer to parity for the first time in a while. So, we should watch that. We will see seasonal production levels start to increase a bit. I don’t know if that will one-for-one find its way into additional whey protein availability, but it certainly should help the situation as we get into heavier production months in the Northern hemisphere markets that produce these products. But other than that, demand remains very, very strong. Prices are firm. They appear they’ll continue to be through at minimum the first quarter. And I don’t think it’s going out on a ledge to say through the first half of the year. And then we’ll see what happens on the other side of it. But yeah, definitely a firm marketplace right now, Ted. Ted Jacoby III: What about milk protein concentrate, milk protein isolate? Are we starting to see the value of those products increase and close the gap between the [00:10:00] whey protein, since the whey proteins have gotten so expensive? Josh White: I’ll jump in and say we’re starting to see some early indications of that: people looking for substitutes where they can. If you’re not in these markets every day, you don’t know what products are available. If you’re in the CPG space or using it as one of many, many SKUs that you’re buying, you’re not aware of the functional properties and some of these other things. And there’s also a decision-making timeline that people have to consider. Not only are there labeling concerns and other things, but there’s a lot of protein that’s consumed as an ingredient and maybe not the primary ingredient. And oftentimes, those decisions are not easy to formulate or change, and they’re also made over larger durations of time, like annual pricing. We’ve had such a wide gap for a long enough time now that we have customers asking questions, and customers that are on the lower end of the valorization for these products are looking for substitutes. Those substitutes come in a couple of ways. They can come from substituting away from dairy, substituting for other [00:11:00] dairy or trading down to lower dairy-related protein products. We’re seeing people investigate all of them. Diego might be able to speak more precisely about what’s happening with the MPC prices. But generally speaking, the majority of people out there are starting to ask questions. I’m not so sure it’s having a material impact or moving the needle quite yet on substitution. Ted Jacoby III: Okay, well, it feels a little bit like a broken record. Milk everywhere, product everywhere except for whey, maybe that’s exactly the loop we’re in right now. Joe Maixner: We’ve talked a lot about supply and excess and whatnot, but demand, it feels like we’re increasingly teetering towards a crumbling economic situation with higher debt, people not having much discretionary income, and just overall demand being weak. Ted Jacoby III: So, if you’re looking at the demand numbers that we track, restaurant traffic is definitely down. It is clear that the economic environment we’re in, people’s pocketbooks are being stretched thin, and they’re cutting back on how often they go to restaurants and eat at [00:12:00] restaurants. Now, usually when that happens, there’s an offset into the retail side, and the retail side numbers usually go up a little bit. You are seeing that. Speaking to some of our branded customers, what they’re telling us is their sales are down, and the private label guys are saying, well, their sales are up, but frankly, not as much as they expected. The bottom has not dropped out yet. I think everybody’s watching it pretty closely. I think the industry’s concerned. I’ll leave it at that. Mike Brown: I think food service continues to be the big stickler on overall dairy sales. Grocery sales are okay. Food service continues to be weak, and that’s gonna affect us. Mm-hmm. Particularly, I think some of the high-fat products. Josh White: When we’re looking at it from the home front, it doesn’t feel real great, but if we’re looking at just how much additional milk we have globally, including out of Oceana and out of South America, and looking at how much of that surplus milk globally is being consumed in Asia right now, I mean they’ve been buying I wonder if that points to some brightness, at least some positives? Now, I also am a little [00:13:00] concerned that we have a consolidation of demand events, with Chinese New Year buying at the same time that Ramadan continues to move earlier and earlier every year. And prices are low right now. Feels like we might have a big concentration of demand that’s meant to satisfy local needs in the early part of 2026, but there has been a lot of international trade. Ted Jacoby III: I think you’re absolutely right. Ramadan and the Chinese New Year are both in February. Diego Carvallo: The word in the street, Ted, is that most of the Ramadan and New Year’s demand is gonna be fulfilled by the middle of November. Ted Jacoby III: In other words, by the time we get to January 1st, those orders are gone. Mike Brown: Yeah. And Super Bowl is 10 days before the start of Ramadan in the Chinese New Year. So, they’re all pretty close together. Josh White: I went back to saying that, hey, we’ve got a lot of milk globally, every surplus region’s producing more milk than expected. You mentioned earlier, Ted, that doesn’t even account for the component growth that we have here. That’s been fairly impressive. [00:14:00] What’s been interesting about that is it hasn’t felt this heavy. You might believe, well, it doesn’t feel as heavy because the Northern Hemisphere is at its low milk production points. Maybe it doesn’t feel as heavy because we’ve got a concentration of additional demand, but we’re trading a lot of anticipatory supply concerns. We’re really trading the fact that tomorrow we’re worried we have a lot of incremental milk, globally, that we don’t necessarily know where we’re gonna go with it. That’s not a reason to get bullish, to be super clear, but I do think that if we’re thinking through vulnerabilities in the market, that might be one. Ted Jacoby III: I would agree with that. I think there are three things that are probably keeping this market from going straight to the bottom. One, as you said, we’re at the low point seasonally for milk production in the Northern Hemisphere. Two, we are at the high point for demand everywhere. And three, you get to a certain point, and I think we are there in all products, we may actually be passed there in butter, but we are there in cheese, I think we’re there in nonfat, where [00:15:00] in order to go lower, you need to build up supply to the point where the inventories become actually burdensome, and I don’t think they have become burdensome yet, but I would expect that sometime in the first quarter of 2026, they will. You’ll start hearing reports that warehouses are full. You’ll start hearing reports that, from a cashflow perspective, whether it’s traders, whether it’s manufacturers, you have people who just need to dump inventory because they don’t have the cash flow to continue to hold inventory. Those are the things that drive markets to their lows. And so, if you think about the old saying: the cure for high prices is high prices, and the cure for low prices is low prices, that’s when you find out what the low price is, and then you go to that place that sends the strongest supply signal possible to suppliers that they need to cut back. Mike Brown: I was at a cattle show of all things this weekend and was talking with someone about feeding palm oil to get butterfat. His rule of thumb was that a pound of palm oil costs about a dollar, and you get about a 00:16:00 three-to-five-point increase in fat test from that. So, if you say 0.4 and you’re a 90-pound Holstein herd, that’s 0.36 pounds of fat. So, you’re paying a dollar to produce, there’s roughly 50, 60 cents worth of butter fat. So, we may start to see that come into conversations on rations. Josh White: And if we’re looking for optimism, I think that formula is pretty openly discussed in Europe as well. So, you’ve got a situation now where you have the on-farm milk price that is beginning to drop, the signals there that it needs to come down. It’s moving at a decent clip, to Diego’s point, maybe not enough to make any major change yet, but for planning purposes, things like feeding for fat might be a bit more vulnerable going forward there. So yeah, if we’re looking for what could start to correct our oversupply situation or what could potentially stabilize or support the market, we need time. I think that’s the most important thing that needs to happen, is we need time, and we need a milk price that curtails any additional production growth [00:17:00] for the moment so that demand can catch up. We talked about the U.S. situation and how the consumer spending situation doesn’t feel great. But globally, per capita butterfat consumption globally is growing. Per capita protein consumption is growing. We just need to give the demand time to catch up. Inventories might be starting to build, but they’re nowhere nearcumbersome. I would actually argue, our supply chain is still very thin. I wouldn’t even argue that we’re getting to a point where we’re normal by historical standards. I think that we have a pretty thin supply chain, and that’s everything from measurable inventory and reports, like cold storage reports and manufacturing stocks here in the U.S., but all the way through the pipeline. I don’t believe that many end users are sitting on excess product or have too many days in inventory. I think they’ve been quite comfortable buying hand-to-mouth. And the only product they’re being punished on right now for that is whey proteins. Ted Jacoby III: I think you’re right, Josh. I would agree with that statement. I think butter [00:18:00] is somewhat of an exception. Joe Maixner: I don’t know. Butter, it just depends on product mix, right? It’s CME eligible salted bulk. I think overall inventories are not burdensome. But we do have too much older CME-eligible salted bulk butter out there. Ted Jacoby III: That’s actually where I’m going, Joe. What do butter manufacturers do if they’re worried about having produced too many quarters and too many solids? They’ll just produce bulk. And so bulk is the overflow because they know the worst-case scenario, they can dump it onto the CME. And so that is where we end up with excess surplus, just like we get the same with a cheddar block in the cheese market. Josh White: How is international demand for U.S. butter at the moment, Joe, compared to where you would expect it to be and compared to where we were a few months ago? Joe Maixner: It’s steady right now. New inquiries are still coming in, but inquiries have lessened compared to a month or two ago; there’s a lot being made and shipping right now. International markets are starting to open their eyes to something other than [00:19:00] 82%. They’re starting to expand into the 80% because they are finally starting to realize that the numbers that they see on the futures don’t equate to the numbers they pay for an 82% product. And so anybody that’s really just using it for solids, for processing, is starting to convert, which is helping clean up some of that 80% salted butter, but it’s still not fast enough to really move the needle yet. Josh White: So, if the outlook for butterfat really doesn’t have any material upside in the near future, and we’re currently looking at Class III and IV prices, where they’re at, when do we start to impact the U.S. producer’s decision on making incremental milk beyond just the fat component? Are we close or are we still a long way away? Jacob Menge: Look at this Milk Production Report. We are up 268,000 head since June of 2024. That just keeps going up. There was an August revision of 71,000 head higher. The answer is a pretty [00:20:00] conclusive, not yet. I’m looking at the last time, September milk production beat the prior month, so beat August, which was 2001. And it just did that; September just beat August, and the last time it did that was 2001. Josh White: We’re not even talking about adjusted for components. Jacob Menge: That is correct. Joe Maixner: I can’t imagine that $16 to $17 Class III causes any worries right now for the farmers, with $4 corn and $1,200 feeder calves. Mike Brown: As long as you’re in a Class III market, if you’re heavy Class IV, your price isn’t $17. It depends on where you’re located, Joe. But for the most part, if you’re in a cheese market, it’s still decent. You’re right because the whey is also contributing a lot to that Class III price right now with a 70¢ whey market. Ted Jacoby III: Yeah. And the cows are all increasing in the states where there is increased processing capacity as well. Jacob Menge: These guys have had time to hedge this, and they still almost can hedge this, right? Going into later next year, where I think it’s gotta be at a point where they can’t hedge at a profit, and then you’ve [00:21:00] really got issues. Josh White: If we’re in a situation where the global economic outlook isn’t great, so that means we shouldn’t expect any major demand booms to pull dairy up We’re realizing supply growth in all major dairy surplus regions; the only correction for this is supply. And who’s the first to react? The obvious answer is it’s gonna be head-to-head with Europe and the U.S. Who breaks first? These are very, very different markets with different drivers, and they’re actually experiencing growth for different reasons related to the big picture, but different reasons. Europe just went through a situation where its butterfat carried the day. And butterfat was incredibly high, much higher than the U.S. price. They were an importer of fat from New Zealand, bringing in a noteworthy amount of product. And then now going into this year, they’ve seen a really significant drop, well below the support level that most traders would’ve held for butterfat. You assume [00:22:00] that they’re not gonna import a bunch of that product, forcing that product on the rest of the market. They’re going through a pretty negative situation right now as well. One thing you can’t forget about the European producer is that if you kill cows, it’s really tough to replace them, not for the same reasons we have in the U.S., that right now it’s just difficult to compete with beef. But they don’t wanna make those changes for a lot of regulatory reasons. So, they’re gonna hang on as long as possible. The U.S. model, we’re not in pain yet, generally speaking. Some smaller producers might look at higher beef prices and lower dairy outlook as an opportunity to exit. But there is way more structural expansion in motion or down the line that I think that train’s moving down the tracks. So, it’ll be really interesting to see if and who breaks first between the North American market and the European market. Ted Jacoby III: My hunch is it’s the U.S. market. I still think we’re a minimum of six months away, maybe even 12 to 18. Now there are signs, like you look at the Milk Production Report, the state of Washington is down [00:23:00] 8.5%. So, there are places where we are losing cows. Even though the majority of the country has gained cows recently, I would argue that with the drop in the butter price and the weakness in the nonfat market, California is the next one that I think will follow. They’ll struggle to get a decent milk price given that those are the two dominant price drivers for the California market. Diego Carvallo: But if you look at Idaho’s strongly up. So, it seems like a movement between Washington and Idaho. Ted Jacoby III: I think you could be right. Joe Maixner: California, their numbers this month were slightly higher than their peak production year 22. They’re on the uptrend. That’s a large ship that takes a while to turn around. Ted Jacoby III: I don’t disagree. I also think you’re still measuring against bird flu in California. You could argue that it may be a little artificially high. Joe Maixner: I actually questioned that because of the lower increase than I had anticipated for the September number, and bird flu didn’t actually start in California until October. So, we will see even larger increases next month forward in California. They [00:24:00] have that Class I plant that they opened as well out there. Mike Brown: They’re also getting hit with a big assessment, a lot of the producers out there, because the butter market changed, there’s been a lot of inventory loss, and that’s gonna hurt some producers as well. No one I talk to in California is worried about finding milk. They’re worried about finding a place to put it right now. Ted Jacoby III: I don’t think that’s isolated to being a California problem right now. Mike Brown: I would agree. You’re right. Ted Jacoby III: On that note, I think it’s a good time to wrap. Thanks, everybody, for joining us this week. Look forward to talking to you guys again soon. Thank you.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor dive into your burning questions from around the world—exploring misunderstood metabolic problems, hard-won solutions for real people, and the science behind the headlines. From “selfish brain” physiology to the rollercoaster of insurance and medication access, Dr. Cooper brings clinical clarity and practical hope.Hear real-world listener stories, get advice on tuning your metabolic health, and learn why personalization—not “calories in, calories out”—leads to better outcomes. This is no silver bullet show: it's metabolic medicine, mythbusting, and science-backed encouragement for your journey.Key Questions AnsweredWhat is the “selfish brain” and how does it really impact blood sugar and diabetes risk?Why do GLP-1 medications affect stamina and hunger, and how should you fuel your body if you're using them?If insurance pulls coverage for medications like Ozempic or Zepbound, what are your practical, safe, and affordable options?How do metabolic markers, medication “cocktails,” and genetic testing shape Dr. Cooper's individualized care—and can you taper off meds and maintain results?What does “normal” blood sugar look like after meals, and how do you distinguish trends from outliers?Key TakeawaysMetabolism is complex—individualized care is essential. Diabetes, hypoglycemia, and insulin resistance all have personal causes and require testing like the Mixed Meal Tolerance Test to solve—not one-size-fits-all advice. GLP-1s require smart fueling. Many experience reduced stamina on these medications. Dr. Cooper recommends upping both complex and simple carbs pre-exercise and consulting with a registered dietitian if fatigue persists. Insurance coverage is a challenge—but not the end. Generic options (like liraglutide/Victoza via Mark Cuban Cost Plus Drugs), manufacturer programs, and “cocktail” regimens can support continued progress, even if you lose access to top-brand GLP-1s. Feedback loops & genetics drive lasting outcomes. While some patients can successfully—slowly—taper medications, most with metabolic dysfunction will need long-term support. “Clean eating” alone rarely reverses underlying feedback loop glitches. Monitoring is powerful. Using blood sugar monitors (especially for diabetics) can demystify meal spikes and help fine-tune nutrition and medication timing. Personal stories reflect broader truths. Listeners share struggles and solutions, reinforcing that metabolic health spans medication, motivation, and mindset.Dr. Cooper's Actionable TipsAlways dig deeper with testing—not just A1C but also post-meal spikes via the Mixed Meal Tolerance Test.If you're prescribed a GLP-1 and struggle with energy, increase carb intake safely and talk to a doctor about medication adjustment. For lost coverage, stick to FDA-approved sources: Lilly Direct for Zepbound, Novocare for Wegovy, and Mark Cuban for generics. Don't risk unregulated online compounds. Recognize the difference between generalized “healthy” habits and targeted strategies that actually move your biomarkers.Stay consistent and compassionate—focus on small improvements over extremes and absolutes.Notable Quote“The metabolism is regulated by a feedback loop…when you introduce outside hormone forms, you strengthen signals to favor fuel utilization over energy conservation.”— Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramGeneric medication access: Mark Cuban Cost Plus DrugsZepbound direct: Lilly DirectAdditional info: Novocare for WegovyFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

Microdosing GLP-1s like Ozempic and Wegovy is the latest buzz in the health world — but is it safe, effective, or even legal? In this episode, I break down the newest research, FDA updates, and expert opinions on microdosing GLP-1 medications. Learn what the science really says, what's still unknown, and why sustainable habits will always matter more than shortcuts.

GLP-1 weight loss drugs like Ozempic, Wegovy, and Tirzepatide are being promoted everywhere but what's missing is the full story. This episode breaks down the hidden GLP-1 side effects most women never hear about, from anxiety and dehydration to vision problems, muscle loss, and disordered eating risks. Chalene exposes how influencer affiliate programs and compounding pharmacies are fueling the hype while lawsuits and safety questions grow. You'll learn what informed consent should actually include, how to protect your metabolism, and why women over 40 need to question what's really behind this weight loss craze. Watch this episode on YouTube this Sunday!! 

After Dark with Hosts Rob & Andrew – Donald Trump comments on falling prices for popular weight-loss medications while reacting sharply to Nancy Pelosi's decision to retire after decades in Congress. Pelosi's legacy, family investments, and past clashes with Trump resurface as federal efforts expand access to drugs like Ozempic and Wegovy, promising savings and broader treatment options for obesity across the United States...

Over the past several years, the rise of GLP-1 drugs such as Ozempic and Wegovy has changed the conversation around weight and obesity in the U.S. Rachel Goldman, PhD, talks about how GLP-1s work; the effects they can have on mental health; what questions to ask if you're considering trying these medications; how weight loss can shift people's relationships with their family, friends and partners; and why there's still stigma around the use of GLP-1s and how patients can navigate that. Find Dr. Rachel's new book at When Life Happens: The Mindset Shift You Need to Manage Stress, Build Confidence, and Break Free. Learn more about your ad choices. Visit megaphone.fm/adchoices

Three more suspects, including two affluent New Jersey teens, are now charged in a foiled ISIS-inspired Halloween terror plot, bringing the total to five. The FAA is cutting up to 10% of flights at 40 major airports as the government shutdown enters week six, triggering nationwide delays. President Trump announces a deal with Eli Lilly and Novo Nordisk to slash the cost of popular GLP-1 weight-loss drugs like Wegovy and Ozempic to about $350 through a new program called TrumpRX. Former House Speaker Nancy Pelosi, 85, announces she will not seek reelection after nearly four decades in Congress and two impeachments of President Trump. Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Walmart: Learn how Walmart is fueling the future of U.S. manufacturing at https://Walmart.com/America-at-work Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.